madman
Super Moderator
* Overall, the available evidence suggests that TRT may provide clinically meaningful improvements in mood for hypogonadal men, particularly those with low baseline testosterone and coexisting depressive symptoms. However, current data do not support its routine use as an antidepressant therapy in eugonadal men.
Depression is a complex mental health condition that affects millions globally.1 It has traditionally been linked to imbalances in key neurotransmitters such as serotonin, norepinephrine, and dopamine, which regulate mood and emotional stability.2 This understanding has shaped the foundation for most modern antidepressant therapies and clinical treatment guidelines.2 However, depression is now recognized as a multifaceted condition with a complex etiology, and neurotransmitter depletion alone cannot fully explain its pathogenesis.2
Emerging evidence has linked low testosterone to specific depressive symptoms and an increased risk of depression, suggesting it may be an important yet underexplored factor in mood regulation.3–5 Testosterone plays a central role in reproduction6 and physical health7,8 and is increasingly recognized as a modulator of mood regulation and emotional stability.9 Disruptions in testosterone levels, particularly in the form of hypogonadism, are associated with a higher risk of depression.1
This narrative review explores the complex relationship between testosterone and depression by synthesizing current evidence on its neurobiological role in mood regulation and evaluating the therapeutic potential of TRT, with emphasis on clinical applications and evidence-based recommendations.
Testosterone production and mechanism of action in mood disorders
Together, these data indicate that testosterone’s mood effects likely arise from the integrated actions of AR signaling, neurotransmitter modulation, and changes in neural circuitry. Disentangling these interconnected pathways in humans will require more rigorous, targeted research, but doing so is critical for interpreting the often complex and sometimes contradictory clinical findings linking testosterone levels to mood symptoms in men.
Clinical evidence linking testosterone and depression
Testosterone and depression in men
In summary, while low testosterone, particularly in hypogonadal men,is consistently associated with increased depressive symptom burden, the broader relationship between testosterone and mood remains complex.
Testosterone and depression in women
These findings caution against the assumption that restoring androgen levels alone will alleviate depressive symptoms in women and underscore the importance of considering the broader hormonal and psychosocial context. Individual hormone sensitivity, receptor-level dynamics, and pre-existing mood disorders likely modulate these effects.59
Ethnicity, androgen sensitivity, and mood disorders
These observations underscore the importance of incorporating genetic and ethnic variability into the assessment of androgen-related mood disorders. Differences in AR sensitivity and testosterone dynamics may influence both symptom presentation and response to TRT. Clinicians should consider these factors when evaluating patients and tailoring treatment strategies, recognizing that uniform diagnostic thresholds and treatment approaches may not fully capture individual variability in androgen-related mood risk.
Testosterone and sexual well-being: Implications for mood and depression
Collectively,the evidence suggests that sexual health,testosterone levels, and mood are interdependent. Disruption in any one of these domains can adversely affect the others, underscoring the need for a holistic understanding of how sexual well-being fits into the broader picture of psychological and hormonal health in both men and women.
Clinical implications of testosterone replacement therapy in mood disorders in men
Overall, the available evidence suggests that TRT may provide clinically meaningful improvements in mood for hypogonadal men, particularly those with low baseline testosterone and coexisting depressive symptoms. However, current data do not support its routine use as an antidepressant therapy in eugonadal men.These findings highlight the importance of appropriate patient selection and suggest that future research should focus on identifying biomarkers, such as AR polymorphisms, that may help predict treatment response in more heterogeneous populations.
Clinical implications of testosterone replacement therapy in mood disorders in women
Despite some promising signals, current guidelines, including those from the Endocrine Society, recommend testosterone therapy primarily for hypoactive sexual desire disorder in women, rather than as a treatment for mood disorders.82 This position reflects the lack of high-quality, long-term data supporting the efficacy and safety of TRT for mood disorders in women
Evaluating the risks of testosterone therapy
Clinical decision-making should remain individualized and patient-centered. Factors such as AR polymorphisms24,25,61 and ethnicity-specific hormonal trajectories61,62 may influence treatment response, although routine genetic testing is not currently part of the standard of care.96 Shared decision-making is essential to ensure that patients understand the expected benefits, uncertainties, and potential risks of therapy , and that decisions align with individual values, mental health goals, and lifestyle considerations.82,96
Future directions
The clinical application of TRT requires individualized treatment plans that account for baseline testosterone levels, age, gender, and coexisting medical conditions. Gender- specific responses warrant additional research to improve our understanding of TRT’s long-term safety and efficacy in women. Furthermore, large-scale randomized controlled trials are needed to establish the efficacy of TRT and develop evidence-based guidelines for its use not only in hypogonadal men, but also in eugonadal men, particularly regarding its potential role as an adjunct to traditional antidepressant therapies. Future research should also explore optimal dosing, therapy duration, and monitoring strategies to mitigate risks and maximize benefits.
Depression is a complex mental health condition that affects millions globally.1 It has traditionally been linked to imbalances in key neurotransmitters such as serotonin, norepinephrine, and dopamine, which regulate mood and emotional stability.2 This understanding has shaped the foundation for most modern antidepressant therapies and clinical treatment guidelines.2 However, depression is now recognized as a multifaceted condition with a complex etiology, and neurotransmitter depletion alone cannot fully explain its pathogenesis.2
Emerging evidence has linked low testosterone to specific depressive symptoms and an increased risk of depression, suggesting it may be an important yet underexplored factor in mood regulation.3–5 Testosterone plays a central role in reproduction6 and physical health7,8 and is increasingly recognized as a modulator of mood regulation and emotional stability.9 Disruptions in testosterone levels, particularly in the form of hypogonadism, are associated with a higher risk of depression.1
This narrative review explores the complex relationship between testosterone and depression by synthesizing current evidence on its neurobiological role in mood regulation and evaluating the therapeutic potential of TRT, with emphasis on clinical applications and evidence-based recommendations.
Testosterone production and mechanism of action in mood disorders
Together, these data indicate that testosterone’s mood effects likely arise from the integrated actions of AR signaling, neurotransmitter modulation, and changes in neural circuitry. Disentangling these interconnected pathways in humans will require more rigorous, targeted research, but doing so is critical for interpreting the often complex and sometimes contradictory clinical findings linking testosterone levels to mood symptoms in men.
Clinical evidence linking testosterone and depression
Testosterone and depression in men
In summary, while low testosterone, particularly in hypogonadal men,is consistently associated with increased depressive symptom burden, the broader relationship between testosterone and mood remains complex.
Testosterone and depression in women
These findings caution against the assumption that restoring androgen levels alone will alleviate depressive symptoms in women and underscore the importance of considering the broader hormonal and psychosocial context. Individual hormone sensitivity, receptor-level dynamics, and pre-existing mood disorders likely modulate these effects.59
Ethnicity, androgen sensitivity, and mood disorders
These observations underscore the importance of incorporating genetic and ethnic variability into the assessment of androgen-related mood disorders. Differences in AR sensitivity and testosterone dynamics may influence both symptom presentation and response to TRT. Clinicians should consider these factors when evaluating patients and tailoring treatment strategies, recognizing that uniform diagnostic thresholds and treatment approaches may not fully capture individual variability in androgen-related mood risk.
Testosterone and sexual well-being: Implications for mood and depression
Collectively,the evidence suggests that sexual health,testosterone levels, and mood are interdependent. Disruption in any one of these domains can adversely affect the others, underscoring the need for a holistic understanding of how sexual well-being fits into the broader picture of psychological and hormonal health in both men and women.
Clinical implications of testosterone replacement therapy in mood disorders in men
Overall, the available evidence suggests that TRT may provide clinically meaningful improvements in mood for hypogonadal men, particularly those with low baseline testosterone and coexisting depressive symptoms. However, current data do not support its routine use as an antidepressant therapy in eugonadal men.These findings highlight the importance of appropriate patient selection and suggest that future research should focus on identifying biomarkers, such as AR polymorphisms, that may help predict treatment response in more heterogeneous populations.
Clinical implications of testosterone replacement therapy in mood disorders in women
Despite some promising signals, current guidelines, including those from the Endocrine Society, recommend testosterone therapy primarily for hypoactive sexual desire disorder in women, rather than as a treatment for mood disorders.82 This position reflects the lack of high-quality, long-term data supporting the efficacy and safety of TRT for mood disorders in women
Evaluating the risks of testosterone therapy
Clinical decision-making should remain individualized and patient-centered. Factors such as AR polymorphisms24,25,61 and ethnicity-specific hormonal trajectories61,62 may influence treatment response, although routine genetic testing is not currently part of the standard of care.96 Shared decision-making is essential to ensure that patients understand the expected benefits, uncertainties, and potential risks of therapy , and that decisions align with individual values, mental health goals, and lifestyle considerations.82,96
Future directions
The clinical application of TRT requires individualized treatment plans that account for baseline testosterone levels, age, gender, and coexisting medical conditions. Gender- specific responses warrant additional research to improve our understanding of TRT’s long-term safety and efficacy in women. Furthermore, large-scale randomized controlled trials are needed to establish the efficacy of TRT and develop evidence-based guidelines for its use not only in hypogonadal men, but also in eugonadal men, particularly regarding its potential role as an adjunct to traditional antidepressant therapies. Future research should also explore optimal dosing, therapy duration, and monitoring strategies to mitigate risks and maximize benefits.
